@article{ATM21385,
author = {Tsuyoshi Hamada and Keisuke Kosumi and Yousuke Nakai and Kazuhiko Koike},
title = {Surrogate study endpoints in the era of cancer immunotherapy},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {The choice of a primary endpoint is a matter of ongoing debate in the design of clinical oncology trials testing new treatment regimens. Overall survival (OS) time of patients serves as a gold-standard endpoint in phase III clinical trials testing first-line chemotherapy for cancers, because this outcome variable ultimately represents survival benefits from chemotherapy regimens and has minimal measurement errors.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21385}
}